Reviewing Capricor Therapeutics Inc. (CAPR)’s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s results – FinanceMercury

This is therefore a comparing of the institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations in Capricor Therapeutics Inc. (NASDAQ:CAPR) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

Demonstrates Capricor Therapeutics Inc. and Brainstorm Cell Therapeutics Inc. earnings per share, top-line revenue and valuation.

Profitability

Table 2 represents Capricor Therapeutics Inc. (NASDAQ:CAPR) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)s return on assets, return on equity and net margins.

Volatility and Risk

A beta of 1.8 shows that Capricor Therapeutics Inc. is 80.00% more volatile than Standard & Poors 500. Brainstorm Cell Therapeutics Inc. has a 1.19 beta and it is 19.00% more volatile than Standard & Poors 500.

Liquidity

Capricor Therapeutics Inc.s Current Ratio and Quick Ratio are 5.3 and 5.3 respectively. The Current Ratio and Quick Ratio of its competitor Brainstorm Cell Therapeutics Inc. are 1 and 1 respectively. Capricor Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Brainstorm Cell Therapeutics Inc.

Analyst Ratings

The following table given below contains the ratings and recommendations for Capricor Therapeutics Inc. and Brainstorm Cell Therapeutics Inc.

$11.5 is Capricor Therapeutics Inc.s average target price while its potential upside is 342.31%. Competitively Brainstorm Cell Therapeutics Inc. has a consensus target price of $9, with potential upside of 134.99%. The data from earlier shows that analysts belief suggest that Capricor Therapeutics Inc. seems more appealing than Brainstorm Cell Therapeutics Inc.

Institutional and Insider Ownership

Capricor Therapeutics Inc. and Brainstorm Cell Therapeutics Inc. has shares owned by institutional investors as follows: 5.1% and 11.4%. Insiders owned 32.93% of Capricor Therapeutics Inc. shares. On the other hand, insiders owned about 0.6% of Brainstorm Cell Therapeutics Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Capricor Therapeutics Inc. has weaker performance than Brainstorm Cell Therapeutics Inc.

Summary

Brainstorm Cell Therapeutics Inc. beats on 7 of the 10 factors Capricor Therapeutics Inc.

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The companys development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Follow this link:
Reviewing Capricor Therapeutics Inc. (CAPR)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - FinanceMercury